# A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects

> **NCT05022810** · PHASE1 · COMPLETED · sponsor: **HALEON** · enrollment: 61 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** New Paracetamol Oral Suspension (24 mg/ml)
- **DRUG:** Panadol B&I Oral Suspension (24 mg/ml paracetamol)

## Key facts

- **NCT ID:** NCT05022810
- **Lead sponsor:** HALEON
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-23
- **Primary completion:** 2021-09-08
- **Final completion:** 2021-09-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022810, "A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05022810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*